Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03053596 Recruiting - Clinical trials for Hepatocellular Carcinoma

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

Start date: November 2016
Phase: N/A
Study type: Observational

The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearls for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment.

NCT ID: NCT03048123 Completed - Clinical trials for Hepatocellular Carcinoma

HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

Start date: October 1, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large and unresectable hepatocellular carcinoma staged BCLC A/B.

NCT ID: NCT03047603 Recruiting - Clinical trials for Hepatocellular Carcinoma

Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC

Start date: May 1, 2016
Phase: N/A
Study type: Observational

The incidence of Hepatocellular carcinoma (HCC) is increasing worldwide. However, most of HCC cases were at advanced stage when the diagnosis established.Early diagnosis improves the prognosis.The study is intended to evaluate the diagnostic efficiency of Protein Induced by Vitamin K Absence or antagonist-II(PIVKA-II). This study is a international multicenter study joined by several hospitals in China,Singapore,Thailand and Vietnam. Participants including healthy control,HCC,metastatic liver cancer,Hepatitis B virus(HBV) and liver cirrhosis are consecutively recruited into the cohort. All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II,alpha-fetoprotein and biochemical indexes including alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma-glutamyl transferase(GGT),alpha-l-fucosidase(AFU),etc.

NCT ID: NCT03046979 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

HCC
Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with advanced HCC.

NCT ID: NCT03045497 Completed - Clinical trials for Hepatocellular Carcinoma

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads

Start date: December 12, 2012
Phase: Phase 1
Study type: Interventional

This pilot clinical trial compares the use of contrast-enhanced ultrasound to contrast-enhanced magnetic response imaging (MRI), the current clinical standard, in predicting treatment response in patients with liver cancer receiving transarterial chemoembolization with drug eluting beads. Comparing results of diagnostic procedures before and after transarterial chemoembolization may help doctors predict a patient's response to treatment and help plan the best treatment. It is not yet known if contrast-enhanced ultrasound works better than contrast-enhanced MRI in predicting treatment response in patients with liver cancer.

NCT ID: NCT03042520 Recruiting - Diabetes Mellitus Clinical Trials

Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment

LONGHEAD
Start date: August 2016
Phase: N/A
Study type: Observational

Primary Objective: To evaluate the long-term outcomes including liver related morbidity, mortality and hepatocellular carcinoma (HCC) development as compared to those of historical control with interferon(IFN)-based treatment. Secondary Objective: 1. To access liver fibrosis progression/regression in CHC patients after sofosbuvir-based treatment. 2. To investigate the long-term outcomes of extrahepatic manifestations of the sofosbuvir-based treated cohort as compared to their pretreatment status.

NCT ID: NCT03040453 Recruiting - Clinical trials for Hepatocellular Carcinoma

Immunological Response After Ablative Therapy in the Liver

IRAL
Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Local ablative treatment of Hepatocellular Carcinoma is performed primary on patients not eligible for liver transplant or liver resection. At our Hospital two different methods are used: Microwave ablation, where the tumor cells are heated up and killed, and Irreversible electroporation, where the tumor cells are exposed to an electrical field and nano-pores are formed in the cell membranes and the cells go into apoptosis (programed cell death). Previous studies have shown effects on the immune system after ablative therapies. The purpose of this study is to compare the immunological response after the wo different methods of killing the tumor cells.

NCT ID: NCT03035006 Not yet recruiting - Clinical trials for HepatoCellular Carcinoma

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Start date: March 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II dose-escalation study of lipotecan based concurrent chemoradiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.

NCT ID: NCT03033446 Recruiting - Clinical trials for HepatoCellular Carcinoma

Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of liver-localised radioembolization and nivolumab on liver cancer.

NCT ID: NCT03024684 Recruiting - Clinical trials for HepatoCellular Carcinoma

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

SHOT
Start date: January 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment